Joint presentation with Pfizer will focus on drivers for the implementation of continuous manufacturing and the development of pod-based mini-factories
Taking to the podium on 2 June at 11:30 AM, Dr Harald Stahl, GEA’s Director of Pharma Applications and Strategy Management, will tackle the hot topic of continuous manufacturing (CM) in the pharmaceutical industry.
Presenting in the 'Manufacturing' track, Dr Stahl’s talk, 'The Holy Grail for Pharma Manufacturers: Continuous Manufacturing — Breaking Away from Conventional Batch Manufacturing Model Used in Pharma,' will address key issues such as the shortfalls of traditional batch processing as a driver for CM and a roadmap for the full implementation of a continuous system.
Joining Dr Stahl, Michael K. O’Brien, PhD, Vice President Technology and Innovation from Pfizer, will discuss the award-winning portable, continuous, miniature and modular (PCMM) concept. Pfizer, GEA and its partners are leading the way toward smaller, more flexible, continuous processing technologies that have the potential to transform the future of pharmaceutical development and manufacturing, and deliver customised quantities of drugs to patients in need in a quick and efficient way. Michael will address these pod-based mini-factories from a hardware/design perspective and their rollout into industry use.
Highlighting the company’s expertise in solid dosage manufacturing, containment, fermentation, homogenisation and process solutions for the production of highly potent actives, GEA will also be exhibiting at the event on booth E21.
CPhI Istanbul and its co-located events bring together local Turkish and regional drug manufacturers with global suppliers of raw materials, machinery, packaging solutions and contract services. The event attracts more than 200 exhibitors and 4000 attendees from the MENA region. The conference sessions are free to attend when you register for CPhI Istanbul.
As a leading innovator of manufacturing concepts, analytical technologies and processing equipment design and optimisation, GEA will continue to play a major role in the global drive to develop continuous oral solid dosage (OSD) production solutions that improve the quality, efficiency and cost-effectiveness of pharmaceutical production for the ultimate benefit of patient health.